Pfizer Could Claim Tukysa First-Line HER2+ Metastatic Breast Cancer Indication

 
• By Joseph Haas
  
Breast Cancer
Pfizer is looking to move Tukysa into first-line maintenance therapy in HER+ MBC (Shutterstock)

More from Clinical Trials

More from R&D